利记·sbobet(中国)-唯一官方网站

Premier Innovative Platform

A global R&D center uniformly operates clinical research projects to ensure maximum R&D efficiency.
We are committed to taking innovative R&D as the core driver for future growth, continuously improving the R&D mechanism of innovator drugs, and continuously increasing the construction of the "4 + 3" R&D platform, that is, four major technology platforms (biologics, innovative small molecule drugs, high-value generic drugs and new technology therapeutic platforms) and three major systems (internal R&D, license-in and in-depth incubation).